ATE398177T1 - Verfahren zur behandlung von erkrankungen im zusammenhang mit apoe - Google Patents

Verfahren zur behandlung von erkrankungen im zusammenhang mit apoe

Info

Publication number
ATE398177T1
ATE398177T1 AT01987564T AT01987564T ATE398177T1 AT E398177 T1 ATE398177 T1 AT E398177T1 AT 01987564 T AT01987564 T AT 01987564T AT 01987564 T AT01987564 T AT 01987564T AT E398177 T1 ATE398177 T1 AT E398177T1
Authority
AT
Austria
Prior art keywords
apoe
methods
carboxyl
invention further
further provides
Prior art date
Application number
AT01987564T
Other languages
English (en)
Inventor
Yadong Huang
Robert W Mahley
Original Assignee
David Gladstone Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Gladstone Inst filed Critical David Gladstone Inst
Application granted granted Critical
Publication of ATE398177T1 publication Critical patent/ATE398177T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT01987564T 2000-11-03 2001-11-02 Verfahren zur behandlung von erkrankungen im zusammenhang mit apoe ATE398177T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24573700P 2000-11-03 2000-11-03

Publications (1)

Publication Number Publication Date
ATE398177T1 true ATE398177T1 (de) 2008-07-15

Family

ID=22927880

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01987564T ATE398177T1 (de) 2000-11-03 2001-11-02 Verfahren zur behandlung von erkrankungen im zusammenhang mit apoe

Country Status (8)

Country Link
US (2) US6787519B2 (de)
EP (1) EP1443816B1 (de)
JP (1) JP4399160B2 (de)
AT (1) ATE398177T1 (de)
AU (1) AU2002239766B9 (de)
CA (1) CA2426030C (de)
DE (1) DE60134430D1 (de)
WO (1) WO2002038108A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053172A2 (en) * 2000-12-29 2002-07-11 Kimberly-Clark Worldwide, Inc. Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover
DE60326153D1 (de) * 2002-07-30 2009-03-26 David Gladstone Inst Verfahren zur diagnose von morbus alzheimer
US7612179B2 (en) * 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
RU2006122946A (ru) * 2003-11-28 2008-01-10 Астразенека Аб (Se) Антитела
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
WO2007075318A2 (en) * 2005-12-07 2007-07-05 The J. David Gladstone Institutes Agents that reduce apoe-induced impairment of mitochondria and methods of use thereof
JP5103466B2 (ja) 2006-03-30 2012-12-19 グラクソ グループ リミテッド アミロイド‐βペプチドに対する抗体
US20090136456A1 (en) * 2006-12-22 2009-05-28 Yadong Huang Methods of treating neurodegenerative disorders
JP2012509888A (ja) * 2008-11-21 2012-04-26 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ ＡｐｏＥ関連障害の治療におけるＡｐｏＥ切断活性の阻害
US20110023140A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Rabbit genome editing with zinc finger nucleases
EP2542581A4 (de) * 2010-03-01 2014-01-22 David Gladstone Inst Apolipoproteinspezifischer antikörper und anwendungsverfahren dafür
EP3757121A1 (de) * 2019-06-28 2020-12-30 Eisai R&D Management Co., Ltd. Fragmente von apolipoprotein e
CN116554303A (zh) * 2022-01-30 2023-08-08 斯莱普泰(上海)生物医药科技有限公司 载脂蛋白E的C端片段及其在抑制γ分泌酶酶活中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252463A (en) * 1990-06-22 1993-10-12 The Du Pont Merck Pharmaceutical Company Clipsin, a chymotrypsin-like protease and method of using same
US5288707A (en) * 1990-08-13 1994-02-22 Sandoz Ltd. Borolysine peptidomimetics
US5650508A (en) * 1991-12-27 1997-07-22 Georgia Tech Research Corporation Peptide ketoamides
GB9502985D0 (en) * 1995-02-16 1995-04-05 Thrombosis Res Inst Enzyme inhibitors
EP0883405B1 (de) * 1995-12-29 2004-02-25 3-Dimensional Pharmaceuticals, Inc. Amidino proteaseinhibitoren
CA2260183A1 (en) * 1996-07-09 1998-01-15 Keith A. Crutcher Methods for the treatment of apolipoprotein e related diseases
JPH1149739A (ja) * 1997-08-05 1999-02-23 Nippon Steel Corp 新規な酸無水物及びキモトリプシン様プロテアーゼ阻害剤
US6046381A (en) * 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods

Also Published As

Publication number Publication date
AU3976602A (en) 2002-05-21
JP4399160B2 (ja) 2010-01-13
US20040268423A1 (en) 2004-12-30
CA2426030C (en) 2013-12-31
AU2002239766B9 (en) 2007-04-05
DE60134430D1 (de) 2008-07-24
JP2004516825A (ja) 2004-06-10
EP1443816B1 (de) 2008-06-11
CA2426030A1 (en) 2002-05-16
WO2002038108A3 (en) 2004-05-06
EP1443816A4 (de) 2004-09-29
EP1443816A2 (de) 2004-08-11
US7700304B2 (en) 2010-04-20
US20020147999A1 (en) 2002-10-10
US6787519B2 (en) 2004-09-07
AU2002239766B2 (en) 2006-11-09
WO2002038108A2 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
ATE398177T1 (de) Verfahren zur behandlung von erkrankungen im zusammenhang mit apoe
McMillan et al. Tau isoform regulation is region‐and cell‐specific in mouse brain
Mucke et al. High-level neuronal expression of Aβ1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation
Casas et al. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ42 accumulation in a novel Alzheimer transgenic model
Postina et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model
ATE170082T1 (de) Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen
Epis et al. Searching for new animal models of Alzheimer′ s disease
ZA200703426B (en) Plants having improved growth characteristics and method for making the same
Janus et al. New developments in animal models of Alzheimer’s disease
ATE445647T1 (de) Nicht-humaner säuger, welcher transgen ist für die konstante region der schweren kette vom humanem klasse a immunoglobulin und verwendung dafür
Hutter et al. Differential roles of miR‐15a/16‐1 and miR‐497/195 clusters in immune cell development and homeostasis
Kobori et al. Large scale isolation of osteoclast‐specific genes by an improved method involving the preparation of a subtracted cDNA library
CA2560551A1 (en) Transgenic model for alzheimer's disease
CN116761508A (zh) 罗非鱼的经基因编辑的白化-红色生殖细胞系
EP2263453B1 (de) Transgenes Tiermodell für neurodegenerative Erkrankungen
MX2007006359A (es) Plantas que tienen caracteristicas de crecimiento mejoradas y metodo para crear las mismas.
DE60232318D1 (de) Gen-targeting-tiermodell für die wechselwirkung der apolipoprotein e4-domäne und verwendungen davon
Thirtamara Rajamani et al. Inactivation of the catalytic phosphatase domain of PTPRT/RPTPρ increases social interaction in mice
ATE389017T1 (de) Verfahren zur selektiven hemmung des menschlichen n-myc-gens in n-myc exprimierenden tumoren durch antisense- und sense-peptidonukleinsäuren (pna)
IL174726A (en) Non-human animals with transgenic nucleic acid encoded by a mutant perinylin 1 protein
Carlson Prion protein and genetic susceptibility to diseases caused by its misfolding
KR100463992B1 (ko) 2차원 젤 전기영동에 의한 염색체 말단의 고리 형성 확인방법
Jayne Investigations of γ-secretase substrates Amyloid precursor protein and p75 neurotrophin receptor in zebrafish
WO2004111189A3 (en) Transgenic animal having an amyloid precursor protein with a modified beta secretase cleavage site
WO2003089609A3 (en) Short fragment homologous replacement to provide bse resistant cattle

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties